Sign inCreate account

Report workspace

Add to folder
NCT03030196COMPLETEDanonymous

Denosumab and Male Infertility: a Randomized Controlled Double-blinded Intervention Study

Sponsor

Source record

Martin Blomberg Jensen

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Denosumab

Indication / condition

AI-normalized

Infertility, Male

Intervention

Source record

Denosumab

Related intelligence directories

Indication directory: InfertilityModality directory: monoclonal antibodyTarget directory: Denosumab

Source & freshness

Source record

NCT ID

NCT03030196

Original source

ClinicalTrials.gov

Source last updated

Jun 13, 2023

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03030196

Title

Denosumab and Male Infertility: a Randomized Controlled Double-blinded Intervention Study

Sponsor

Martin Blomberg Jensen

Status

COMPLETED

Phase

PHASE2

Condition raw

Infertility, Male

Condition normalized

Infertility, Male

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Denosumab

Target normalized

Denosumab

Interventions

Denosumab

Public preview

Source record

To determine the significance of systemic RANKL inhibition for male reproduction, conducting a clinical controlled randomized double blinded intervention study on infertile men, to investigating whether Denosumab (Prolia) can increase semen quality and to investigate what subgroup of infertile men that might benefit from treatment.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Denosumab and Male Infertility: a Randomized Controlled Double-blinded Intervention Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT03030196

Status

COMPLETED

Phase

PHASE2

Sponsor

Martin Blomberg Jensen

Executive brief

Investment-Ready Snapshot

To determine the significance of systemic RANKL inhibition for male reproduction, conducting a clinical controlled randomized double blinded intervention study on infertile men, to investigating whether Denosumab (Prolia) can increase semen quality and to investigate what subgroup of infertile men that might benefit from treatment.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 13, 2023
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03030196

Indication

Infertility, Male

Modality

monoclonal antibody

Target

Denosumab

Intervention

Denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.